Highlights and Quick Summary
- EBITDA Margin for the quarter ending June 30, 2023 was -74.31% (a 9.05% increase compared to previous quarter)
- Year-over-year quarterly EBITDA Margin increased by 1975.7%
- Annual EBITDA Margin for 2022 was -2.26% (a -108.43% decrease from previous year)
- Annual EBITDA Margin for 2021 was 26.8% (a -24.46% decrease from previous year)
- Annual EBITDA Margin for 2020 was 35.48% (a 72.23% increase from previous year)
- Twelve month EBITDA Margin ending June 30, 2023 was -37.32% (a 107.33% increase compared to previous quarter)
- Twelve month trailing EBITDA Margin decreased by -281.69% year-over-year
Trailing EBITDA Margin for the last four month:
| 30 Jun '23 | 31 Mar '23 | 31 Dec '22 | 30 Sep '22 |
|---|---|---|---|
| -37.32% | -18.0% | -2.26% | 20.54% |
Visit stockrow.com/EBS
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EBITDA Margin of Emergent Biosolutions Inc.
Most recent EBITDA Marginof EBS including historical data for past 10 years.Interactive Chart of EBITDA Margin of Emergent Biosolutions Inc.
Emergent Biosolutions Inc. EBITDA Margin for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | -74.31% | -68.14% | – | – | – |
| 2022 | -8.62% | -3.58% | -10.92% | 12.46% | -2.26% |
| 2021 | 42.53% | -0.27% | 12.25% | 36.47% | 26.8% |
| 2020 | 49.42% | 23.62% | 39.37% | 8.99% | 35.48% |
| 2019 | 29.49% | 31.78% | 9.17% | 0.05% | 20.6% |
| 2018 | 13.74% | 19.41% | 35.92% | 2.46% | 19.54% |
| 2017 | 34.82% | 38.53% | 18.32% | 21.46% | 30.06% |
| 2016 | 40.18% | 32.09% | 7.55% | 29.13% | 29.4% |
| 2015 | 67.06% | 45.28% | 23.96% | -31.08% | 36.14% |
| 2014 | 82.03% | 29.01% | 14.79% | -34.56% | 30.07% |
| 2013 | 29.26% | 26.17% | 22.95% | -21.32% | 19.75% |
| 2012 | 29.12% | 18.9% | – | – | 14.6% |
Business Profile of Emergent Biosolutions Inc.
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic